Etravirine (ETR,[3]), sold under the brand name Intelence is an antiretroviral medication used for the treatment of HIV.

[1] Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI).

[6] Etravirine is licensed in the United States, Canada, Israel, Russia, Australia, New Zealand, and the European Union,[7] and is under regulatory review in Switzerland.

[2] People with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this etravine.

[9] In 2009, the FDA prescribing information for etravirine was modified to include "postmarketing reports of cases of Stevens–Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme, as well as hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver failure.